Arcutis Total Current Liabilities from 2010 to 2025
| ARQT Stock | USD 17.11 0.18 1.04% |
Total Current Liabilities | First Reported 2018-12-31 | Previous Quarter 172.4 M | Current Value 81 M | Quarterly Volatility 34.4 M |
Check Arcutis Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arcutis Biotherapeutics' main balance sheet or income statement drivers, such as Interest Expense of 28.5 M, Selling General Administrative of 240.9 M or Total Revenue of 206.4 M, as well as many indicators such as Price To Sales Ratio of 8.14, Dividend Yield of 0.0 or PTB Ratio of 11.23. Arcutis financial statements analysis is a perfect complement when working with Arcutis Biotherapeutics Valuation or Volatility modules.
Arcutis | Total Current Liabilities |
Latest Arcutis Biotherapeutics' Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of Arcutis Biotherapeutics over the last few years. Total Current Liabilities is an item on Arcutis Biotherapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Arcutis Biotherapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Arcutis Biotherapeutics' Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Arcutis Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
Arcutis Total Current Liabilities Regression Statistics
| Arithmetic Mean | 19,995,353 | |
| Geometric Mean | 4,114,309 | |
| Coefficient Of Variation | 145.34 | |
| Mean Deviation | 23,313,441 | |
| Median | 2,673,000 | |
| Standard Deviation | 29,062,061 | |
| Sample Variance | 844.6T | |
| Range | 84.4M | |
| R-Value | 0.84 | |
| Mean Square Error | 260.4T | |
| R-Squared | 0.71 | |
| Significance | 0.00004 | |
| Slope | 5,151,651 | |
| Total Sum of Squares | 12669.1T |
Arcutis Total Current Liabilities History
About Arcutis Biotherapeutics Financial Statements
Arcutis Biotherapeutics shareholders use historical fundamental indicators, such as Total Current Liabilities, to determine how well the company is positioned to perform in the future. Although Arcutis Biotherapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Arcutis Biotherapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Arcutis Biotherapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 81 M | 85.1 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arcutis Stock Analysis
When running Arcutis Biotherapeutics' price analysis, check to measure Arcutis Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcutis Biotherapeutics is operating at the current time. Most of Arcutis Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Arcutis Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcutis Biotherapeutics' price. Additionally, you may evaluate how the addition of Arcutis Biotherapeutics to your portfolios can decrease your overall portfolio volatility.